Focus

Opthea is committed to improving vision in patients suffering from retinal eye diseases.

We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies.

OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.

LEARN MORE

Disease

Wet AMD is the leading cause of blindness in the developed world in people aged over 50 years. It is caused by the abnormal growth and leakage of blood vessels at the back of the eye, which causes degeneration of the retina and vision loss.

Learn More

Technology

Opthea’s technology is centered on two members of the Vascular Endothelial Growth Factor (VEGF) family of proteins, VEGF-C and VEGF-D, and their activation of VEGF receptors. These proteins promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3, and lymphatic vessel development (lymphangiogenesis), by activation of VEGFR-3.

Learn More

Opportunity

Both wet AMD and DME are associated with vascular dysfunction and fluid accumulation at the back of the eye in a region of the central retina or ‘macula’ that is needed for sharp, central vision. Vessel growth and vascular leakage are primarily driven by members of the vascular endothelial growth factor (VEGF) family, which comprises 5 members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF).

Learn More

OPT-302

OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Learn More

Clinical Trials

Opthea initiated two pivotal Phase 3 clinical trials for the treatment of wet AMD in the first half of 2021. Opthea has completed three international clinical trials investigating OPT-302 in two disease indications.  Two of the trials were in wet AMD patients including a first in human Phase 1b/2a study followed by  a large randomized controlled Phase 2bstudy, whilst the third trial was aPhase 1b/2a study in patients with DME.

Learn more

WITH CLINICAL TRIALS PROGRESSING
AND DATA LOOKING PROMISING,
WE BELIEVE OPT-302 WILL IMPROVE
OUTCOMES FOR PATIENTS WITH
THESE DEBILITATING DISEASES.

Opthea Researcher

Announcements

Opthea Presentation at The Retina World Congress 2022

10th May 2022

Opthea Presented at the Retina World Congress 2022, taking place in Fort Lauderdale, Florida from May 12-15, 2022

Read More

Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

5th May 2022

Clinical data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The presentation, titled “Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy,” was held on Sunday, May 1, 2022

Read More

Opthea strengthens its Board of Directors

26th April 2022

Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives at a General Meeting of Shareholders.

Read More

Opthea appoints Dr. Joel Naor M.D as Chief Medical Officer

2nd March 2022

Opthea is pleased to announce the appointment of Dr. Joel Naor as Chief Medical Officer, effective 1 March 2022.

Read More

ALL ANNOUNCEMENTS